Cargando…
Venom immunotherapy: safety and tolerability of the build‐up phase with depot versus aqueous preparations
Autores principales: | Pravettoni, Valerio, Mauro, Marina, Rivolta, Federica, Consonni, Dario, Cappelletti, Camilla, Chiei Gallo, Alessandra, Sangalli, Andrea, Bilò, Maria Beatrice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796821/ https://www.ncbi.nlm.nih.gov/pubmed/35904013 http://dx.doi.org/10.1111/cea.14209 |
Ejemplares similares
-
Successful fractionated undiluted doses of COVID‐19 vaccine in five cases of suspected allergic reactions to the first dose
por: Rivolta, Federica, et al.
Publicado: (2022) -
Successful adalimumab graded challenge after allergic delayed reaction to golimumab in a woman with rheumatoid arthritis
por: Rivolta, Federica, et al.
Publicado: (2023) -
Remission of a case of multiple Hymenoptera stings‐associated chronic urticaria during venom immunotherapy
por: Dubini, Marco, et al.
Publicado: (2021) -
Determinants of venom-specific IgE antibody concentration during long-term wasp venom immunotherapy
por: Pravettoni, Valerio, et al.
Publicado: (2015) -
464 Specific Venom Ige Decrease during 5 Years of Venom Immunotherapy (VIT): Clinical Relevance in Stung and Not Stung Patients
por: Pravettoni, Valerio, et al.
Publicado: (2012)